Latest Annexon Biosciences News & Updates

See the latest news and media coverage for Annexon Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Annexon Biosciences

Developer of C1q inhibitors for complement-driven diseases

annexonbio.com
Headquarters
South San Francisco, United States
Founded year
2011
Company type
Public company
Number of employees
100–200
Industry
Pharmaceuticals

Last updated

Latest news about Annexon Biosciences

In short: Annexon Biosciences advanced its neuroimmunology pipeline by filing for regulatory approval of tanruprubart and progressing phase 3 trials.

Company announcements

Annexon Biosciences

Annexon reports Q4 and year-end 2025 financial results

Highlights portfolio progress including ARCHER II data expected Q4 2026, tanruprubart MAA filed, $238.3M cash runway to H2 2027. Net loss $48.3M for Q4, $208.5M for year.

Unlock all announcements with a

Media coverage

The Globe and Mail

Annexon Biosciences Secures $200 Million Credit Facility

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities...

Yahoo Finance

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

Annexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates acros...

Unlock all articles with a

Never miss news about Annexon Biosciences

Track Annexon Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.